Introduction
Over the past several decades, the importance of the stroma to cancer progression has become increasingly recognized. Rather than existing in isolation, cancer cells are surrounded by a tumor microenvironment that is largely the product of pancreatic stellate cells (PSC) that are sometimes referred to as stromal or cancer-associated fibroblasts. The tumor microenvironment also includes other cells such as immune cells and adipocytes as well as vascular and lymphatic networks and prominent extracellular matrix. In both chronic pancreatitis and in pancreatic adenocarcinoma (PAC) the stroma is problematic because it is quite extensive. In particular, the desmoplastic nature of PAC contributes to the limited surgical options for most patients at the time of diagnosis. Furthermore, recent evidence indicates that in PAC the stroma influences chemoresistance and metastasis. (2, 5) Most in vivo studies of PAC use orthotopic or even in some cases subcutaneous models formed by injection of cancer cells only. In addition, we use cancer cells labeled with firefly luciferase to allow monitoring of primary tumor growth and development of metastases in real time. This non-invasive imaging is extremely useful with orthotopic tumors which cannot be accurately measured by conventional means without sacrificing the animal.
In this chapter, the methods for using an orthotopic co-injection model of PAC will be outlined. 7. Use a 30-gauge needle and 1-ml syringe for injection.
Materials

B. Surgical procedure
1. Anesthetize animal-our lab uses ketamine (100 mg/kg) + xylazine (2.5 mg/kg), intraperitoneal injection using 27-ga needle.
Clean the left flank with alcohol wipe, or
Betadine-soaked gauze.
3. Identify ribs on left side and lift skin of left flank (subcostal region) with forceps and snip the skin and subcutaneous layer of muscle/peritoneum (0.5-1 cm length). To enter the abdominal cavity, you may need to open the skin and muscle/peritoneum with 2 cuts. This spot should be just inferior to the ribs, and slightly anterior.
4. Identify the spleen. The pancreas is located just deep to the spleen, and looks thin and white, or very pale pink/tan. Don't confuse the pancreas with mesenteric fat.
5.
With the left hand, pick up the tail of the pancreas with smooth forceps (not forceps with teeth as this will damage the pancreas).
6. With the right hand, take a moistened Q-tip and roll it under the pancreas tail to "splay" out the pancreas.
7. Use the left hand to gently grasp the tail of the pancreas with smooth forceps and stretch it out very gently towards yourself.
8. Use the right hand to inject the cells slowly (50 ul volume) into the tail of the pancreas, just under the capsule. A wheal or bubble should form, just as in a subQ injection. Keep both hands steady to avoid leakage of the cells.
9. Keep the needle in the pancreas until after you stop injecting. Then, pull the needle out slowly.
10. Immediately press a dry Q-tip on the injection site to absorb any cells that have leaked.
Hold pressure for a few seconds.
11. Replace the pancreas and spleen into the peritoneal cavity.
12. Wipe the inside of the incision site (in all directions) with a Q-tip moistened with 70% EtOH to minimize wound tumor formation.
13. Close the wound with metal clips. Usually 2 clips should completely close the small incision. Be sure to close both the peritoneum/muscle and skin, otherwise a hernia will develop! If using metal clips, closing the 2 layers as one layer is fine, otherwise, if using sutures, they need to be closed separately.
14. Post-procedure recovery: allow mouse to recover under a heat lamp or other warmer.
C. IVIS imaging
1. Prepare a fresh stock solution of luciferin at 15mg/ml in DPBS. Inject 10 ul/g of body weight. Each mouse should receive 150 mg luciferin/kg body weight. (e.g. For a 10 g mouse, inject 100 ul to deliver 1.5 mg of luciferin.)
2. Inject the luciferin intra-peritoneally (i.p.) 10-15 minutes before imaging*.
* A luciferin kinetic study should be performed for each animal model to determine peak signal time.
Results
Using this model, we showed that co-injection of PSCs resulted in increased growth of the primary pancreatic tumor and metastases.(2) The influence of PSCs was dose-dependent since a tumor:stroma ratio of 1:5 resulted in greater tumor growth than a ratio of 1:1 (Figure 1) . Furthermore, the presence of PSCs increased the incidence of tumor formation when limiting numbers of cancer cells were injected. Thus, PSCs may also be involved in tumor initiation as well as tumor progression. There are limitations to this model. One limitation is that despite the inclusion of the PSCs, in our experiments using Bxpc3 cancer cells, there was no significant increase in the level of stroma developed in the tumors formed by co-injection with PSCs compared to tumors with cancer cells alone. This observation suggested that the coinjected PSCs did not persist through the full period of the studies, which was subsequently confirmed (unpublished observation). Nevertheless, in a model using AsPC-1 cancer cells co-injected with PSCs, increased collagen deposition was observed in the tumors, confirming that the injected PSCs influence stromal development. (5) 
